Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00028366 · ClinicalTrials.gov registry record · NA
Dual Versus Triple Protease Inhibitor Combinations, Including Ritonavir, in HIV Infected People
A NA study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- NA
- Development phase
- 56
- Enrollment target
NCT00028366: Completed NA study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00028366 is a NA study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 56 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00028366, a NA study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- NA
- Development phase
- 56 participants
- Enrollment target
Study Summary
Ritonavir (RTV) is a protease inhibitor (PI) commonly used to increase drug levels of other PIs in HIV drug treatment. The purpose of this study is to compare a combination of drugs which includes RTV and 2 protease inhibitors (PIs) with 2 combinations that include RTV and another PI. This study also will compare the effectiveness, safety, tolerability, and drug levels in the blood of these anti-HIV drug combinations.
Interventions
- DRUG Ritonavir
- DRUG Lopinavir/Ritonavir
- DRUG Tenofovir disoproxil fumarate
- DRUG Fosamprenavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Est. Completion | 2005-07 |
| Phase | NA |
What the finished NCT00028366 record still lists
NCT00028366 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 4 interventions - of which Ritonavir is the first listed.
NCT00028366 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00028366 about?
NCT00028366 is a clinical study titled "Dual Versus Triple Protease Inhibitor Combinations, Including Ritonavir, in HIV Infected People". Ritonavir (RTV) is a protease inhibitor (PI) commonly used to increase drug levels of other PIs in HIV drug treatment. The purpose of this study is to compare a combination of drugs which includes RTV and 2 protease inhibitors (PIs) with 2 combinations that include RTV and another PI. This study als...
What is the current status of trial NCT00028366?
This trial is currently completed. It is a NA study. The enrollment target is 56 participants. Estimated completion is 2005-07.
What interventions are being tested in trial NCT00028366?
The interventions under investigation include: Ritonavir (DRUG), Lopinavir/Ritonavir (DRUG), Tenofovir disoproxil fumarate (DRUG), Fosamprenavir (DRUG).
Who is sponsoring clinical trial NCT00028366?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00028366's enrollment target sits among peer trials
56 1262nd of 2000 higher than 737 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management